ReviewEndocrine pathology2015
Mesenchymal stem cells in the treatment of type 1 diabetes mellitus.
Review in Endocrine pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Characterization of MSCs expressing islet neogenesis associated protein (INGAP): INGAP secretion and cell survivalHeliyon · 2024Article
- The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.Biological research · 2024Article
- Wharton's jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications.Frontiers in cell and developmental biology · 2023Review
- 2D and 3D cultured human umbilical cord-derived mesenchymal stem cell-conditioned medium has a dual effect in type 1 diabetes model in rats: immunomodulation and beta-cell regeneration.Inflammation and regeneration · 2022Article
- Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.Cells · 2022Review
- New therapeutic approaches of mesenchymal stem cells-derived exosomes.Journal of biomedical science · 2021Review
- Transcriptome analysis of the transdifferentiation of canine BMSCs into insulin producing cells.BMC genomics · 2021Article
- Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.Journal of diabetes and metabolic disorders · 2020Review
- Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.Frontiers in cell and developmental biology · 2020Review
- Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease.Scientific reports · 2019Article
- MIST1, an Inductive Signal for Salivary Amylase in Mesenchymal Stem Cells.International journal of molecular sciences · 2019Article
- A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.Stem cell investigation · 2019Review
- Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?Frontiers in immunology · 2019Review
- Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America.Diabetology & metabolic syndrome · 2019Review
- Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders.International journal of molecular sciences · 2018Review
- Stem cell therapy in autism: recent insights.Stem cells and cloning : advances and applications · 2018Review
- Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering.Stem cells international · 2018Review
- Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.World journal of stem cells · 2017Review
- Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on Osteopenia.Theranostics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.